RECRUITING

MRS Measurement of Glutamate and GABA Metabolism in Brain

Talk to us

Conditions

Normal PhysiologyGlutamateExcitatory Amino AcidNeurochemistryBrainMagnetic Resonance Spectroscopy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of \[13\]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).

Official Title

MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain

Quick Facts

Study Start:2006-09-06
Study Completion:2030-03-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00109174

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-65 years of age
  2. * Able to give written informed consent
  3. * Healthy based on medical history and physical exam
  4. * Enrolled in Protocol 01-M-0254 or Protocol 17-M-0181
  1. * Any current Axis 1 diagnosis
  2. * Clinically significant laboratory abnormalities
  3. * Positive HIV test
  4. * Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
  5. * History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury
  6. * Prescription psychotropic medication; drug free less than 8 weeks (anticholinergics, benzodiazepine, fluoxetine, antipsychotics, and anticonvulsants)
  7. * Serious medical illness as determined from H\&P or laboratory testing including Diabetes
  8. * Inability to lie flat on camera bed for about two and a half hours
  9. * Pregnant or breastfeeding
  10. * Current substance use disorder based on DSM-5
  11. * NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.

Contacts and Locations

Study Contact

Christopher S Johnson
CONTACT
(301) 402-6695
johnsonchri@mail.nih.gov
Li An, Ph.D.
CONTACT
(301) 896-2882
anl@mail.nih.gov

Principal Investigator

Li An, Ph.D.
PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Institute of Mental Health (NIMH)

  • Li An, Ph.D., PRINCIPAL_INVESTIGATOR, National Institute of Mental Health (NIMH)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2006-09-06
Study Completion Date2030-03-11

Study Record Updates

Study Start Date2006-09-06
Study Completion Date2030-03-11

Terms related to this study

Keywords Provided by Researchers

  • Glutamate
  • Excitatory Amino Acid
  • Neurochemistry
  • Brain
  • Magnetic Resonance Spectroscopy

Additional Relevant MeSH Terms

  • Normal Physiology